Medtronic PLC $MDT Shares Acquired by Invesco Ltd.

Invesco Ltd. boosted its holdings in Medtronic PLC (NYSE:MDT) by 3.9% during the second quarter, HoldingsChannel.com reports. The fund owned 17,647,149 shares of the medical technology company’s stock after acquiring an additional 666,557 shares during the period. Invesco Ltd.’s holdings in Medtronic were worth $1,538,302,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in shares of Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the period. XTX Topco Ltd acquired a new stake in shares of Medtronic in the first quarter valued at approximately $680,000. TIAA Trust National Association grew its holdings in Medtronic by 80.6% in the 1st quarter. TIAA Trust National Association now owns 12,770 shares of the medical technology company’s stock worth $1,148,000 after buying an additional 5,699 shares in the last quarter. Raiffeisen Bank International AG increased its position in Medtronic by 98.8% in the 1st quarter. Raiffeisen Bank International AG now owns 18,880 shares of the medical technology company’s stock valued at $1,654,000 after acquiring an additional 9,381 shares during the period. Finally, Westfield Capital Management Co. LP bought a new stake in Medtronic during the 1st quarter valued at $7,226,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on MDT shares. Stifel Nicolaus increased their price target on Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Truist Financial increased their target price on shares of Medtronic from $103.00 to $110.00 and gave the company a “hold” rating in a research report on Thursday, November 20th. Robert W. Baird raised their target price on shares of Medtronic from $103.00 to $109.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. Finally, UBS Group increased their price objective on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $110.44.

Medtronic Trading Down 1.3%

NYSE:MDT opened at $101.99 on Wednesday. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33. The stock has a fifty day simple moving average of $96.37 and a 200 day simple moving average of $91.94. The firm has a market capitalization of $130.76 billion, a price-to-earnings ratio of 28.10, a price-to-earnings-growth ratio of 2.42 and a beta of 0.71. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the firm posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.